The addition of DTPA to[177Lu-DOTA0, Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 30, Issue 2, 2003, Pages 312-315

  Breeman, Wouter A P ^a   Van der Wansem, Katy ^a   Bernard, Bert F ^a   Van Gameren, Arthur ^a   Erion, Jack L ^b   Visser, Theo J ^a   Krenning, Eric P ^a   De Jong, M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Biosynthema   (United States)

Author keywords

Biodistribution; DOTA; DTPA; Radiolabelling

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID OCTREOTIDE[3 TYROSINE DOTA LUTETIUM 177]; LUTETIUM 177; LUTETIUM TETRACHLORIDE 177; PENTETIC ACID; PENTETIC ACID LU 177; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN; UNCLASSIFIED DRUG; (177LUTETIUM DOTA(O)TYR3)OCTREOTATE; (177LUTETIUM-DOTA(O)TYR3)OCTREOTATE; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10-TETRAAZACYCLODODECANE- 1,4,7,10-TETRAACETIC ACID; LUTETIUM; ORGANOMETALLIC COMPOUND; RADIOISOTOPE; RADIOPROTECTIVE AGENT; SINGLE HETEROCYCLIC RINGS;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BONE; BONE MARROW; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DISTRIBUTION; EPIPHYSIS PLATE; FEMUR; IN VITRO STUDY; IN VIVO STUDY; IRRADIATION; ISOTOPE LABELING; LIVER; MALE; NONHUMAN; RADIATION DOSE; RADIOACTIVITY; RAT; SKELETON; SPLEEN; URINARY EXCRETION; ANIMAL; ANTIBODY SPECIFICITY; COMPARATIVE STUDY; DRUG EFFECT; EVALUATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; METABOLISM; METHODOLOGY; RADIOMETRY; SCINTISCANNING; TISSUE DISTRIBUTION; WISTAR RAT;

ANIMALS; BONE MARROW; FEMUR; HETEROCYCLIC COMPOUNDS, 1-RING; INJECTIONS, INTRAVENOUS; KIDNEY; LUTETIUM; MALE; ORGAN SPECIFICITY; ORGANOMETALLIC COMPOUNDS; PENTETIC ACID; RADIATION-PROTECTIVE AGENTS; RADIOISOTOPES; RADIOMETRY; RADIOPHARMACEUTICALS; RATS; RATS, WISTAR; TISSUE DISTRIBUTION;

EID: 0038176450     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-002-1054-4     Document Type: Article

References (9)

1. Breeman WA, de Jong M, Kwekkeboom DJ, et al. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 2001: 28:1421-1429.
2. 0]octreotide in patients. Eur J Nucl Med 2001; 28:1319-1325.
3. 3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer 2001; 92:628-633.
4. Li WP, Ma DS, Higginbotham C, et al. Development of an in vitro model for assessing the in vivo stability of lanthanide chelates. Nucl Med Biol 2001; 28:145-154.
5. Muller WA, Schaffer EH, Linzner U. Studies on incorporated short-lived beta-emitters with regard to the induction of late effects. Radiat Environ Biophys 1980; 18:1-11.
6. Muller WA, Linzner U, Schaffer EH. Organ distribution studies of lutetium-177 in mouse. Int J Nucl Med Biol 1978; 5:29-31.
7. 1]-octreotide for detection of somatostatin receptor-positive tumors in rats. Life Sci 1991; 49:1593-1601.
8. O'Mara RE, McAfee JG, Subramanian G. Rare earth nuclides as potential agents for skeletal imaging. J Nucl Med 1969; 10:49-51.
9. Mackie EJ, Trechsel U, Bruns C. Somatostatin receptors are restricted to a subpopulation of osteoblast-like cells during endochondral bone formation. Development 1990; 110:1233-1239.